AAN 2021: Intranasal Zavegepant Effective in Alleviating Pain and Other Acute Migraine Symptoms
No hepatotoxicity was observed, and the 10-mg dose will be evaluated in phase III trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.